Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc. (LXRX) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
lxrx · stock forecast · 14 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 14 Wall Street analysts in the past 3 months
Hold
14 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$6.00
Consensus
$6.00
+214.1% upside
Low
$6.00
Median: $6 · Last Close: $1.91
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $1.81 | ↓ 5.00% |
1-day model range: $1.8–$1.83. Peak: $1.83 (-5.00%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $4 | +120.0% |
| 2028 | $7 | +265.2% |
| 2029 | $10 | +397.8% |
| 2030 | $11 | +497.1% |
| 2031 | — | +562.7% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · LXRX · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-05-11 | Citigroup | Maintains | Buy→Buy |
| 2026-03-23 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-03-10 | Citigroup | Maintains | Buy→Buy |
| 2026-03-05 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-09-02 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-08-07 | Citigroup | Maintains | Buy→Buy |
| 2025-06-24 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-03-28 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-03-07 | Needham | Maintains | Hold→Hold |
| 2025-03-07 | HC Wainwright & Co. | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Lexicon Pharmaceuticals, Inc. (LXRX) stock. Of the recent 80 rating actions, 5 were upgrades and 11 were downgrades. 14 analysts currently cover LXRX.
Analyst Recommendation Trends
LXRX analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 4 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$38M
↓ 49.9% YoY
Revenue Next Year
$20M
↓ 47.2% YoY
EPS This Year
$-0.16
EPS Next Year
$-0.21
↑ 30.0% YoY
EPS ForecastReported vs Estimated
Analysts forecast LXRX EPS of $-0.16 for the current fiscal year, based on estimates from 3 analysts. The LXRX revenue forecast is $38M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The LXRX stock forecast is supported by two independent data sources: analyst consensus ratings from 14 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus LXRX price target is $6.00 (+214.1% upside), with an analyst consensus of Hold.
The LXRX short-term stock prediction for tomorrow is $1.81 (-5.00%). The LXRX stock price prediction for 2027 estimates an average of $4. The LXRX stock prediction for 2030 projects a range of $10–$13.
Lexicon Pharmaceuticals, Inc. trades on NASDAQ under the ticker LXRX. The LXRX stock outlook for 2027 is broadly mixed, supported by a Hold consensus among 36% of covering analysts.
Frequently asked questions
LXRX forecast · 8 questionsAccording to 14 Wall Street analysts, the average 12-month LXRX price target is $6.00, with a high forecast of $6.00 and a low of $6.00. The median price target is shown in the chart above when available. This implies +214.1% potential upside from the current price of $1.91.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.